RxSight (RXST)
(Delayed Data from NSDQ)
$59.31 USD
-2.11 (-3.44%)
Updated May 10, 2024 04:00 PM ET
After-Market: $59.20 -0.11 (-0.19%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for RxSight, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 89 | 49 | 23 | 15 | NA |
Cost Of Goods | 35 | 28 | 18 | 13 | NA |
Gross Profit | 54 | 21 | 5 | 2 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 104 | 85 | 57 | 37 | 0 |
Income After Depreciation & Amortization | -50 | -63 | -53 | -35 | 0 |
Non-Operating Income | 5 | 2 | 8 | 64 | NA |
Interest Expense | 3 | 5 | 4 | 1 | NA |
Pretax Income | -49 | -67 | -49 | 28 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -49 | -67 | -49 | 28 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -49 | -67 | -49 | 28 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -60 | -48 | -32 | 0 |
Depreciation & Amortization (Cash Flow) | -2 | 3 | 4 | 4 | NA |
Income After Depreciation & Amortization | -50 | -63 | -53 | -35 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 34.46 | 27.66 | 13.63 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.41 | -2.41 | -3.78 | NA | NA |
Diluted Net EPS (GAAP) | -1.41 | -2.41 | -3.57 | NA | NA |
Fiscal Year end for RxSight, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 28.58 | 22.20 | 20.81 | 17.49 |
Cost Of Goods | NA | 10.93 | 8.47 | 8.80 | 7.12 |
Gross Profit | NA | 17.65 | 13.73 | 12.02 | 10.37 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 28.50 | 26.24 | 25.64 | 23.47 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -10.85 | -12.51 | -13.62 | -13.10 |
Non-Operating Income | NA | 1.66 | 0.34 | 1.42 | 1.39 |
Interest Expense | NA | 0.00 | 0.23 | 1.57 | 1.51 |
Pretax Income | NA | -9.20 | -12.40 | -13.78 | -13.21 |
Income Taxes | NA | -0.02 | 0.01 | 0.03 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.18 | -12.42 | -13.80 | -13.21 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.18 | -12.42 | -13.80 | -13.21 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 35.96 | 35.66 | 34.50 | 31.64 |
Diluted EPS Before Non-Recurring Items | NA | -0.26 | -0.35 | -0.40 | -0.42 |
Diluted Net EPS (GAAP) | NA | -0.24 | -0.35 | -0.40 | -0.42 |